492 related articles for article (PubMed ID: 35458763)
1. Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates.
Bouyahya A; El Hachlafi N; Aanniz T; Bourais I; Mechchate H; Benali T; Shariati MA; Burkov P; Lorenzo JM; Wilairatana P; Mubarak MS; El Omari N
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458763
[TBL] [Abstract][Full Text] [Related]
2. The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions.
Bouyahya A; Mechchate H; Oumeslakht L; Zeouk I; Aboulaghras S; Balahbib A; Zengin G; Kamal MA; Gallo M; Montesano D; El Omari N
Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327559
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
[TBL] [Abstract][Full Text] [Related]
4. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.
Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A
Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602
[TBL] [Abstract][Full Text] [Related]
5. Natural Agents-Mediated Targeting of Histone Deacetylases.
Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
7. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy.
Patra S; Panigrahi DP; Praharaj PP; Bhol CS; Mahapatra KK; Mishra SR; Behera BP; Jena M; Bhutia SK
Cell Mol Life Sci; 2019 Sep; 76(17):3263-3282. PubMed ID: 30982077
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of inflammation: progressing from broad acting histone deacetylase (HDAC) inhibitors to targeting specific HDACs.
Cantley MD; Haynes DR
Inflammopharmacology; 2013 Aug; 21(4):301-7. PubMed ID: 23341163
[TBL] [Abstract][Full Text] [Related]
10. An insight into therapeutic efficacy of heterocycles as histone-modifying enzyme inhibitors that targets cancer epigenetic pathways.
Basha NJ; Basavarajaiah SM
Chem Biol Drug Des; 2022 Nov; 100(5):682-698. PubMed ID: 36059065
[TBL] [Abstract][Full Text] [Related]
11. Post-translational modifications talk and crosstalk to class IIa histone deacetylases.
Guttzeit S; Backs J
J Mol Cell Cardiol; 2022 Jan; 162():53-61. PubMed ID: 34416247
[TBL] [Abstract][Full Text] [Related]
12. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
14. Human neuronal cells: epigenetic aspects.
Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases (HDACs) as therapeutic target for depressive disorders.
Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M
Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
[TBL] [Abstract][Full Text] [Related]
18. The role of histone deacetylase 3 in breast cancer.
Rahbari R; Rasmi Y; Khadem-Ansari MH; Abdi M
Med Oncol; 2022 May; 39(5):84. PubMed ID: 35578147
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
Li Z; Zhu WG
Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
